Zevra Therapeutics, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Zevra Therapeutics, Inc. (ZVRA) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $4.68 per share for the 12-month period ending 2023-12-31, per its 10-K filed 2024-04-01.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2024-04-01
- Zevra Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $4.68, a 25.95% decline from fiscal 2022.
- Zevra Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $6.32, a 33.33% decline from fiscal 2021.
- Zevra Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2021 was $9.48, a 81.96% increase from fiscal 2020.
- Zevra Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2020 was $5.21, a 183.15% increase from fiscal 2019.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|
| 2023-12-31 | $4.68 10-K · filed 2024-04-01 |
| 2022-12-31 | $6.32 10-K · filed 2023-03-07 |
| 2021-12-31 | $9.48 10-K · filed 2022-03-31 |
| 2020-12-31 | $5.21 10-K · filed 2021-03-12 |
| 2019-12-31 | $1.84 10-K · filed 2020-02-28 |
| 2018-12-31 | $5.54 10-K · filed 2019-03-01 |
| 2017-12-31 | $3.59 10-K · filed 2018-03-30 |
| 2016-12-31 | $13.31 10-K · filed 2017-03-10 |
| 2015-12-31 | $16.30 10-K · filed 2016-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |